Thioridazine: resurrection as an antimicrobial agent?
Identifieur interne : 002D55 ( Pmc/Corpus ); précédent : 002D54; suivant : 002D56Thioridazine: resurrection as an antimicrobial agent?
Auteurs : H K R. ThanacoodySource :
- British Journal of Clinical Pharmacology [ 0306-5251 ] ; 2007.
Abstract
The emergence of multiresistant bacterial strains and the continuing burden of infectious disease globally point to the urgent need for novel affordable antimicrobial drugs. Thioridazine is a phenothiazine antipsychotic drug with well-recognized antimicrobial activity, but this property has not been harnessed for clinical use as a result of its central nervous system and cardiac side-effects. The cardiotoxicity of thioridazine has recently been shown to be structurally specific at a molecular level, whereas its antimicrobial properties are shared by a number of phenothiazine analogues. This raises the possibility that its enantiomers or its inactive metabolite, the ring sulphoxide, may act as a lead compound in the future development of antimicrobial drugs to face the new challenges in infectious disease.
Url:
DOI: 10.1111/j.1365-2125.2007.03021.x
PubMed: 17764469
PubMed Central: 2203271
Links to Exploration step
PMC:2203271Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Thioridazine: resurrection as an antimicrobial agent?</title><author><name sortKey="Thanacoody, H K R" sort="Thanacoody, H K R" uniqKey="Thanacoody H" first="H K R" last="Thanacoody">H K R. Thanacoody</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">17764469</idno><idno type="pmc">2203271</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2203271</idno><idno type="RBID">PMC:2203271</idno><idno type="doi">10.1111/j.1365-2125.2007.03021.x</idno><date when="2007">2007</date><idno type="wicri:Area/Pmc/Corpus">002D55</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002D55</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Thioridazine: resurrection as an antimicrobial agent?</title><author><name sortKey="Thanacoody, H K R" sort="Thanacoody, H K R" uniqKey="Thanacoody H" first="H K R" last="Thanacoody">H K R. Thanacoody</name></author></analytic><series><title level="j">British Journal of Clinical Pharmacology</title><idno type="ISSN">0306-5251</idno><idno type="eISSN">1365-2125</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>The emergence of multiresistant bacterial strains and the continuing burden of infectious disease globally point to the urgent need for novel affordable antimicrobial drugs. Thioridazine is a phenothiazine antipsychotic drug with well-recognized antimicrobial activity, but this property has not been harnessed for clinical use as a result of its central nervous system and cardiac side-effects. The cardiotoxicity of thioridazine has recently been shown to be structurally specific at a molecular level, whereas its antimicrobial properties are shared by a number of phenothiazine analogues. This raises the possibility that its enantiomers or its inactive metabolite, the ring sulphoxide, may act as a lead compound in the future development of antimicrobial drugs to face the new challenges in infectious disease.</p></div></front></TEI><pmc article-type="review-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="publisher-id">bcp</journal-id><journal-title>British Journal of Clinical Pharmacology</journal-title><issn pub-type="ppub">0306-5251</issn><issn pub-type="epub">1365-2125</issn><publisher><publisher-name>Blackwell Science Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17764469</article-id><article-id pub-id-type="pmc">2203271</article-id><article-id pub-id-type="doi">10.1111/j.1365-2125.2007.03021.x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Thioridazine: resurrection as an antimicrobial agent?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Thanacoody</surname><given-names>H K R</given-names></name></contrib><aff><institution>Royal Infirmary of Edinburgh</institution><addr-line>Edinburgh, UK</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><bold>Correspondence Dr H. K. R. Thanacoody, MD, FRCP(Edin),</bold> Consultant Physician, Royal Infirmary Edinburgh, 51 Little France Crescent, Edinburgh, UK. <bold>Tel:</bold> + 44 13 1242 1293 <bold>Fax:</bold> + 44 13 1242 1387 <bold>E-mail:</bold><email>ruben.thanacoody@luht.scot.nhs.uk</email></corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2007</year></pub-date><pub-date pub-type="epub"><day>31</day><month>8</month><year>2007</year></pub-date><volume>64</volume><issue>5</issue><fpage>566</fpage><lpage>574</lpage><history><date date-type="received"><day>11</day><month>5</month><year>2007</year></date><date date-type="accepted"><day>03</day><month>7</month><year>2007</year></date></history><copyright-statement>© 2007 The Author; Journal Compilation © 2007 Blackwell Publishing Ltd</copyright-statement><copyright-year>2007</copyright-year><abstract><p>The emergence of multiresistant bacterial strains and the continuing burden of infectious disease globally point to the urgent need for novel affordable antimicrobial drugs. Thioridazine is a phenothiazine antipsychotic drug with well-recognized antimicrobial activity, but this property has not been harnessed for clinical use as a result of its central nervous system and cardiac side-effects. The cardiotoxicity of thioridazine has recently been shown to be structurally specific at a molecular level, whereas its antimicrobial properties are shared by a number of phenothiazine analogues. This raises the possibility that its enantiomers or its inactive metabolite, the ring sulphoxide, may act as a lead compound in the future development of antimicrobial drugs to face the new challenges in infectious disease.</p></abstract><kwd-group><kwd>antimicrobial</kwd><kwd>drug development</kwd><kwd>drug resistance</kwd><kwd>QT prolongation</kwd><kwd>thioridazine</kwd><kwd>tuberculosis</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D55 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002D55 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:2203271
|texte= Thioridazine: resurrection as an antimicrobial agent?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:17764469" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |